Hassan Hashmi, General and Colorectal Surgeon at Las Vegas Surgical Associates, shared a post on X about a recent article by Koji Ando et al, published in Annals of Surgery:
“Important data in rectal cancer management. This prospective cohort study in Annals of Surgery demonstrates that postoperative ctDNA (MRD) is a powerful predictor of recurrence and identifies patients who truly benefit from adjuvant chemotherapy after upfront rectal cancer surgery in patients with stage II–III disease.
Importantly, this signal appears independent of conventional staging and current indications for adjuvant therapy. ctDNA-negative patients derived no clear benefit from ACT, whereas ctDNA-positive patients showed a significant DFS advantage.
These findings support a precision, biology-driven approach and position ctDNA as a potentially pivotal factor in postoperative decision-making rather than reliance on stage alone.
As ctDNA continues to mature, this may redefine how we individualize care in rectal cancer.
Open to thoughts and perspectives from leaders in the field.”
Title: Molecular Residual Disease and Recurrence in Rectal Cancer Patients Undergoing Upfront Surgery
Authors: Koji Ando, Atsushi Hamabe, Yoshiaki Nakamura, Jun Watanabe, Keiji Hirata, Kozo Kataoka, Masaaki Miyo, Kentaro Kato, Naoya Akazawa, Yoshinori Kagawa, Mitsuru Yokota, Kentaro Yamazaki, Saori Mishima, Hiroki Yukami, Daisuke Kotani, Hideaki Bando, George Laliotis, Shruti Sharma, Charuta C. Palsuledesai, Matthew Rabinowitz, Adham Jurdi, Minetta C. Liu, Alexey Aleshin, Hiroya Taniguchi, Ichiro Takemasa, Takeshi Kato, Takayuki Yoshino, Eiji Oki
Read the full article on Annals of Surgery.
More posts featuring Hassan Hashmi on OncoDaily.